In a recent announcement, the pan-Canadian Pharmaceutical Alliance (pCPA) and the Canadian Generic Pharmaceutical Association (CGPA) have reached a consensus on a new three-year pricing initiative for generic drugs. The initiative is set to kick off on October 1, 2023. Moreover, the agreement has been structured with the flexibility of a two-year extension, thereby potentially extending its scope to 2028.
This new pricing measure replaces the preceding five-year agreement that was due to expire in 2023. In the interest of continuity and fiscal sustainability, the new three-year pricing strategy aims to facilitate affordable access to generic medication for Canadians.
In addition to this pricing initiative, the pCPA made news with the appointment of Douglas Clark as its first-ever CEO. As a seasoned professional with significant leadership experience, Clark is expected to bring substantial value to the organization.
The pCPA’s joint initiative with the CGPA showcases their commitment to fostering sustainable and affordable generic drug pricing while maintaining a thriving pharmaceutical industry.
Find out more about this development here.